FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent

11.03.08 - 22:45 ... source : Schering-Plough

... Committee Recommends FDA Approve Novel Anesthesia Drug to Reverse Muscle relaxation within Minutes KENILWORTH, N.J., March 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Schering-Plough (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) Advisory Committee on Anesthetics and Life Support has recommended sugammadex for approval. After reviewing data on the safety and efficacy of the medication, the committee unanimously recommended approval of the company's application for marketing. The FDA is not bound by the committee's recommendations; however, they usually are considered carefully before a final decision on approval is made. Upon FDA approval, sugammadex will be the first and only selective relaxant binding agent (SRBA) and will give anesthesiologists the ability to rapidly and predictably reverse any ...» Next (HTML)